Citation Impact
Citing Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
2015
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
2017
Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
2014
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
2018
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
2020 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Thymoquinone and its therapeutic potentials
2015 Standout
The immune contexture in cancer prognosis and treatment
2017 Standout
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
2013
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Metagenomics for the study of viruses in urban sewage as a tool for public health surveillance
2018
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts
2011
First- and Second-Line Therapy for Metastatic Urothelial Carcinoma of the Bladder
2011
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
Bladder cancer
2016 Standout
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum
2011
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
New Therapeutic Challenges in Advanced Bladder Cancer
2012
Epidemiology and Risk Factors of Urothelial Bladder Cancer
2012 Standout
Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
2011
Clonal evolution of chemotherapy-resistant urothelial carcinoma
2016
Vinflunine
2011
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
2017
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
2017
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine
2011
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Molecular biology and targeted therapies for urothelial carcinoma
2015
SARS-CoV-2 in wastewater: State of the knowledge and research needs
2020 Standout
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
2015
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
2017
Bladder Cancer
2020 Standout
Neue Ziele für die Photopharmakologie
2016 StandoutNobel
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Avelumab for the treatment of urothelial cancer
2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
2018
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Natural product and natural product derived drugs in clinical trials
2014 Standout
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
2010
Strategies for Combining Immunotherapy with Radiation for Anticancer Therapy
2015 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Emerging Targets in Photopharmacology
2016 StandoutNobel
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
2010
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
CTLA-4 and PD-1 Pathways
2015 Standout
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
2011
An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
2013
Second-Line Systemic Therapy for Metastatic Urothelial Carcinoma of the Bladder
2013
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute
2016 StandoutNobel
Works of B. K. Komyakov being referenced
Detection of DNA viruses in prostate cancer
2016
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
2009
Metagenomic sequencing of expressed prostate secretions
2014